Latest News
- Psoriasis
Wednesday, February 13, 2019
Two New Psoriasis Guidelines Address Comorbidities, Biologic Treatment
The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines outlining best practices for treating psoriasis with a focus on comorbidities and biologic tr…
Read the full story
Tuesday, February 05, 2019
Biologics May Reduce Plaque Buildup in Psoriasis Patients’ Arteries
Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the National…
Read the full storyFriday, February 01, 2019
Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meeting
Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late…
Read the full storyThursday, January 31, 2019
Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasis
Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, accord…
Read the full storyMonday, January 28, 2019
New Data Show Cosentyx Improves Quality of Life in Patients Being Treated for Psoriasis
Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported …
Read the full story
Wednesday, January 23, 2019
Alan Menter, MD Receives Outstanding Researcher and Educator in Psoriatic Disease Award from ODAC, JDD
Alan Menter, MD, has been awarded the Outstanding Researcher and Educator in Psoriatic Disease Award by the ODAC Dermatology, Aesthetics & Surgical Conference, in partnership with the Journal…
Read the full story
Thursday, January 03, 2019
Bristol-Myers Squibb to Acquire Celgene
Bristol-Myers Squibb Company will acquire Celgene Corp. in a cash and stock transaction with an equity value of approximately $74 billion. The combined company with complementary areas of focus, will …
Read the full story
Tuesday, December 11, 2018
Dermatologists Need More Info About Cannabinoids
Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned a…
Read the full storyTuesday, December 04, 2018
New PsA Guidelines from National Psoriasis and Rheumatology Orgs Recommend Treat-to-Target Approach
Newly released psoriatic Arthritis (PsA) treatment guidelines from the National Psoriasis Foundation (NPF) and the American College of Rheumatology (ACR) are calling for a treat-to-target approac…
Read the full storyWednesday, November 28, 2018
Study: Lipid that Aids Normal Skin Turnover May Help Psoriasis
A lipid that helps keep skin cell turnover on track may help restore healthy turnover in psoriasis, investigators say. Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of…
Read the full storyWednesday, November 28, 2018
Encore Dermatology Announces Phase 2 Safety Data for Impoyz
A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-trea…
Read the full storyWednesday, November 07, 2018
Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasis
Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final appr…
Read the full storyWednesday, October 24, 2018
IBD Linked to Psoriasis in Large Meta-Analysis
A new meta-analysis comprising more than 7 million people suggests it may be time to add inflammatory bowel disease (IBD) to the list of comorbidities associated with psoriasis. The findi…
Read the full story
Tuesday, October 23, 2018
Ilumya Now Available for Moderate-to-Severe Plaque Psoriasis
Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA …
Read the full storyThursday, October 18, 2018
Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europe
Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission …
Read the full story
